Abbott India

Global healthcare company Abbott on Monday announced the launch of a dual-chamber leadless pacemaker system, which will help the heart beat properly without wires or surgical pockets used in traditional pacemakers. Pacemakers help keep the heart beating at a healthy pace, especially in the case of bradycardia, a condition where the heart beats too slowly. In a statement, Abbott said its implant-to-implant device technology enables wireless communication and synchronisation between two leadless pacemakers, which are smaller than an AAA battery. Until recently, leadless pacemakers could only support one chamber of the heart, because getting two separate devices to work together in sync was a major challenge. "As leadless pacing technology has evolved, we've built upon our AVEIR VR single-chamber platform to expand the benefits of leadless pacing to far more people and provide additional treatment options to patients," said Ajay Singh Chauhan, General Manager for Abbott's cardiac rhyt

Pharma stocks came under pressure after President Trump announced a 25 per cent tariff rate for Indian exports to the US

Here is the complete list of stocks going ex-dividend next week, along with their respective dividend announcements, and record dates

Abbott India, Aurobindo Pharma, Cipla, Dr Lal PathLabs and Torrent Pharma flag caution signals on technical charts; here are the key levels to watch out for.

The pharmaceutical company's stock rose as much as 3.86 per cent during the day to ₹31,500 per share

Abbott India's Q4FY25 profit grew 28% year-on-year to ₹367 crore on stronger sales, with revenue at ₹1,605 crore and a final dividend of ₹475 per share announced

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

The company's Q3 profit increased 16 per cent year-on-year (Y-o-Y) to Rs 360.78 crore as compared to Rs 310.98 crore

The surge in Abbott India share price followed reports that JPMorgan, a New York-based financial services firm, raised its target price to Rs 31,500, up from Rs 30,000, signaling an upside of 12%

Drug firm Abbott has launched a pacemaker in India for the treatment of patients with slow heart rhythms. Abbott has introduced AVEIR VR single-chamber ventricular leadless pacemaker which has been approved by the Central Drugs Standard Control Organisation, the company said in a statement on Friday. The product has also been approved by the US Food and Drug Administration (USFDA). "The AVEIR VR leadless pacemaker was designed to make the implantation and retrieval processes as seamless as possible for physicians and provide improvements over existing options," said Ajay Singh Chauhan, General Manager for Abbott's Cardiac Rhythm Management business in India, Southeast Asia, HK, Taiwan & Korea. People who experience slower-than-normal heart rhythm may receive a pacemaker to deliver pulses of electricity to trigger the heart to beat properly. Balbir Singh, Chairman Cardiology, Max Superspeciality Hospital said, "Leadless pacemakers address known complications associated with ...

Pentids are widely prescribed for treating bacterial infections of the respiratory tract, throat, lungs, nose, skin, and sexually transmitted diseases like syphilis

The uptick in the pharma company's stock price came after it posted a healthy set of numbers in the June quarter of financial year 2025 (Q1FY25).

Drug firm Abbott India on Wednesday said its net profit increased by 13 per cent year on year to Rs 328 crore for the first quarter ended June 30, 2024. The company reported a net profit of Rs 290 crore in the April-June quarter of last fiscal. Total income rose to Rs 1,625 crore for the period under review as against Rs 1,535 crore in the June quarter of FY24, Abbott India said in a regulatory filing. Shares of the company on Wednesday ended 1.29 per cent up at Rs 28,159.95 apiece on the BSE.

Abbott India's profit jumped 24.1 per cent to Rs 287.1 crore in the March quarter of FY24 (Q4FY24), from Rs 231.4 crore in the March quarter of FY23 (Q4FY23)

The drugmaker's revenue from operations increased to Rs 1,439 crore, a 7 per cent increase from the Rs 1,343 crore recorded in Q4 FY23

Technical outlook on stocks with high rollover to May series: Keep a tab on these key support and resistance levels while trading in these F&O stocks.

The company's Year-on-Year revenue growth of 8.3% exceeded expectations and its top line was aided by a product mix led by therapies

Firm's revenues were in line with estimates and operational parameters better than expected

The company, which makes popular antacid medicine Digene, said its profit rose to 3.11 billion rupees ($37.5 million) from 2.47 billion rupees a year earlier

The two laxative brands together have estimated annual sales of $70 million in India, healthcare data firm Pharmarack says